Skip to main content

Table 4 Evolution of concomitant treatment and interventions during the study period a

From: Half-molar sodium lactate infusion improves cardiac performance in acute heart failure: a pilot randomised controlled clinical trial

Time points Intervention Control Lactate
Baseline Vasopressors 9 9
  Vasopressor dose (μg/kg/min) 0.04 ± 0.06 0.07 ± 0.1
  Levosimendan (0.1 μg/kg/min) 5 4
  Dobutamine 1 0
  IABP 2 4
  Invasive ventilation 10 14
  Noninvasive ventilation 5 1
24 hours Vasopressors 7 3
  Vasopressor dose (μg/kg/min) 0.03 ± 0.05 0.03 ± 0.1
  IABP 2 4
  Invasive ventilation 9 10
  Noninvasive ventilation 5 0
48 hours Vasopressors 2 3
  Vasopressor dose (μg/kg/min) 0.01 ± 0.03 0.04 ± 0.1
  IABP 2 3
  Invasive ventilation 4 9
  Noninvasive ventilation 1 2
  1. aIABP = Intraaortic balloon counterpulsation device. Vasopressors are noradrenaline or adrenaline. Levosimendan (12.5 mg) was administered at 0.1 μg/kg/min over the course of 24 hours during the study period. Infusions were always started prior to study enrolment. All data are expressed as number of patients, except for vasopressor dose, for which data are expressed as mean ± SD.